Open AccessRituximab-induced subacute interstitial pneumonitis: A case report and review of literature
Author(s) -
Murali Subramanian,
R Manjunath,
Nalini Kilara,
K.N. Mohan Rao
Publication year - 2010
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.73356
Subject(s) - rituximab , medicine , interstitial pneumonitis , cd20 , cryptogenic organizing pneumonia , lymphoma , pneumonitis , hypersensitivity pneumonitis , prednisone , pneumonia , interstitial lung disease , pathology , gastroenterology , lung , respiratory disease
Rituximab is a chimeric anti-CD20 monoclonal antibody used to treat CD20+ non-Hodgkin's lymphoma (NHL). Some pulmonary adverse reactions such as cough, rhinitis, bronchospasm and dyspnea are relatively common. Severe respiratory conditions like cryptogenic organizing pneumonia, interstitial pneumonitis have rarely been reported. We present a case of interstitial pneumonitis in a patient who was treated with R-CHOP for extranodal NHL. He responded to the steroids.